Table 2.
Seropositivity rate against poliovirus strains.
| Poliovirus Strain | Visit 1 | Visit 2 | Visit 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n/N | % | (95%CI) | n/N | % | (95%CI) | n/N | % | (95%CI) | ||
| Sabin | Sabin 1 | 54/61 | 88.5 | (77.8–95.3) | 60/61 | 98.4 | (91.2–100) | 61/61 | 100 | (94.1–100) |
| Sabin 2 | 58/61 | 95.1 | (86.3–99.0) | 61/61 | 100 | (94.1–100) | 61/61 | 100 | (94.1–100) | |
| Sabin 3 | 32/61 | 52.5 | (39.3–65.4) | 60/61 | 98.4 | (91.2–100) | 61/61 | 100 | (94.1–100) | |
| Virulent | Mahoney (type 1) | 44/61 | 72.1 | (59.2–82.9) | 60/61 | 98.4 | (91.2–100) | 61/61 | 100 | (94.1–100) |
| MEF-1 (type 2) | 57/61 | 93.4 | (84.1–98.2) | 61/61 | 100 | (94.1–100) | 61/61 | 100 | (94.1–100) | |
| Saukett (type 3) | 19/61 | 31.1 | (19.9–44.3) | 60/61 | 98.4 | (91.2–100) | 61/61 | 100 | (94.1–100) | |
| Type 2 vaccine-derived polioviruses (VDPV) |
SV3128 | 57/61 | 93.4 | (84.1–98.2) | 61/61 | 100 | (94.1–100) | 61/61 | 100 | (94.1–100) |
| SV3130 | 57/61 | 93.4 | (84.1–98.3) | 61/61 | 100 | (94.1–100) | 61/61 | 100 | (94.1–100) | |
| 11196 | 57/61 | 93.4 | (84.1–98.4) | 61/61 | 100 | (94.1–100) | 61/61 | 100 | (94.1–100) | |
| 11198 | 54/61 | 88.5 | (77.8–95.3) | 61/61 | 100 | (94.1–100) | 61/61 | 100 | (94.1–100) | |
n, number of participants with seropositive titer; N, number of participants with valid serology data; CI, confidence interval.